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BRIEF REPORTS

Asthma is associated with Increased mortality in individuals with
sickle cell anemia
Jessica H. Boyd, Eric A. Macklin, Robert C. Strunk, Michael R. DeBaun

ABSTRACT
From the Department of Pediatrics,
Division of Allergy and Pulmonary
Medicine, Washington University
School of Medicine, St. Louis, MO,
USA (JHB, RCS); New England
Research Institutes, Watertown,
MA, USA (EAM); Department of
Pediatrics, Division of Genetics,
Washington University School
of Medicine, St. Louis, MO, USA
(MRDB).

An analysis of a prospective cohort of individuals with sickle cell anemia (SCA),
enrolled from birth through adulthood, was conducted to determine if asthma is a risk
factor for death in SCA. All-cause mortality was determined for participants after
adjusting for known risk factors for death in SCA. The study included 1,963 individuals who were followed for 18,495 patient-years. After controlling for established risk
factors, individuals with SCA and asthma had a more than two-fold higher risk of mortality (hazard ratio 2.36, 95% CI 1.21 to 4.62, p=0.01). To summarize, asthma is a
risk factor for death in SCA.
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he Co-operative Study for Sickle Cell
Disease (CSSCD), a large, multi-center
natural history study of sickle cell disease, determined the life expectancy for individuals with sickle cell anemia (SCA) to be in
the fifth decade of life after adjustment for
previously identified risk factors including
white blood cell count (WBC), fetal hemoglobin level (HbF), presence of renal failure,
seizures, and acute chest syndrome (ACS.1
Asthma is a common chronic illness that
affects approximately 9% of AfricanAmerican adults2 and 15% of AfricanAmerican children.3-6 It is associated with an
increased incidence of ACS and painful
episodes among children with SCA(7). The
contribution of asthma to premature death
has not been assessed in individuals with
SCA. Given the established association
between asthma and pain and ACS in this
same cohort,7-9 and the recognized risk of
death in patients with even a single episode of
ACS,10 we used data collected prospectively
over the 20-year term of the CSSCD to test
the hypothesis that a concurrent diagnosis of
asthma in patients with SCA is associated
with increased mortality.

T

Design and Methods
Study design
The CSSCD study design has been previously reported.1,11,12 Participants were assessed
at least once for asthma on a supplemental
history form and/or a pulmonary function
intake form. Original consent and assent
were obtained in accordance with the
requirements of the human subjects committees at participating clinical centers.
Additional Institutional Review Board
approval was obtained from Washington
University School of Medicine for analysis of
the de-identified data held by the National
Heart, Lung, and Blood Institute. The cohort
for this study included African-American participants with hemoglobin SS enrolled in the
CSSCD from birth to 61 years of age.
Participants who died before the age of five
(n=33) or were not followed beyond the age
of five (n=45) were excluded from this study.
This is because a diagnosis of asthma is
unclear in young children, and death from
bacterial infection in children under the age of
5 was frequent in the era of the CSSCD study.
Of the 2,557 individuals enrolled, 76.8%
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(n=1,963) had adequate clinical data to classify asthma.
Follow-up for mortality data was censored for loss to follow-up or bone-marrow transplant.

Table 1. Demographics of patients with sickle cell anemia that
were evaluated for asthma.

Asthma cases
(n=138)

Controls
(n=1825)

p
value

65 (47%)

872 (48%)

0.93

9.7
0.0 to 47.9

14.2
0.0 to 61.4

<0.001

14.0
5.0 to 53.9

20.2
5.0 to 67.4

<0.001

10.8
3.0 to 19.6

9.3
4.6 to 19.8

<0.001

Classification
Asthma. Asthma was classified by a clinical diagnosis of
asthma recorded during the medical history, an acute asthma event during the study period, or use of prescribed
asthma medications on a clinic visit form. Based on available evidence, an assumption is made that asthma, a
chronic condition, is a life-long illness.13
Death. An event reported on a form completed by the
CSSCD site investigator at the time of the event. The etiology of death and confirmation of the cause of death was
not uniform across the study period. Therefore, for this
analysis, all-cause mortality was used.

Gender – no. (%)
Male
Age at entry – yrs
Mean
Range
Asthma Dx Age1 – yrs
Mean
Range
Follow-up2 ( yrs)
Mean
Range

1
Age is the time when asthma diagnosis was first assessed. 2Follow-up for the
cohort is between date of entry and loss to follow-up or death.

Data analysis was performed in SAS, version 9.1.
Demographic parameters were compared between subjects classified for asthma using t-tests and Fisher’s exact
test. Time to death was summarized using Kaplan-Meier
product-limit estimates and tested by Cox regression.
Analysis of deaths included left-truncation of the at-risk
interval from birth to date of entry. Mortality (median age
at death) was compared for individuals with and without
asthma. In addition to asthma classification, Cox regression analysis included the following co-variates and previously established risk factors for death: age, WBC count,
renal failure, HbF level, seizure, and ACS.1 Laboratory values were determined based on the average of all values
during follow-up, excluding laboratory values during acute
events and HbF percent before the age of 2. The proportional hazards assumption was tested and supported by
inspecting martingale residuals and by testing for a timedependent effect of asthma.

Results and Discussion
Demographics
A total of 1,963 African American individuals with SCA
who were classifiable for asthma enrolled in the study and
were followed for a total of 18,495 patient-years. The
demographic features of the cohort are listed in Table 1. A
total of 138 individuals (7.0%) had asthma; 70% (97/138)
were classified by a physician’s diagnosis, 10% by documentation of an acute asthma event, and 20% by the
recorded of use of a prescribed asthma medication (betaagonist, inhaled corticosteroid, theophylline, inhaled nonsteroidal anti inflammatory medication). The 594 individuals who could not be classified for asthma were older
(mean age: 16.4 yrs.) and had shorter follow-up (mean follow-up: 7.3 yrs.) when compared to those included in the
cohort for analysis.
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Figure 1. Kaplan-Meier plot of age of death for subjects with sickle cell anemia and asthma (n=138) and those without asthma
(n=25) conditional on survival beyond age 5 years. Relative survivorship given here is conservative because asthmatic subjects
were enrolled at younger ages and mortality risk increases with
age.

Asthma and sickle cell anemia-related mortality
Asthma was associated with a significant increase in the
risk of all-cause mortality (Figure 1). The median life span
for individuals with and without asthma who survived to
the age of 5 was 52.5 and 64.3 years of age respectively.
After controlling for age, WBC count, HbF level, renal failure, seizures, and ACS rate, individuals with SCA and
asthma had over a two-fold higher mortality risk when
compared to children with SCA without asthma (hazard
ratio 2.36 by Cox regression, 95% CI 1.21 to 4.62, p=0.01,
Table 2). In the CSSCD, the average life span for adults
with SCA was determined to be in the fifth decade of life.
Several co-morbid conditions including seizures, renal failure, and ACS were determined to be risk factors for mortality in this cohort.1 However, these analyses did not
include an assessment of asthma, a recently described
common co-morbid condition that is associated with an
increased risk of pain and ACS.7 The present analysis of
data from this cohort has determined that asthma is a sig-

Asthma mortality in sickle cell disease

Table 2. Cox regression estimates of mortality predictors, including estimates from both the final multivariate model and each predictor in a univariate model.

N

Multivariate Model
Hazard ratio (95% CI)

p value

N

Univariate Models
Hazard ratio (95% CI)

p value

1828

0.779 (0.709,0.856)

<0.0001

2635

1.005 (0.956,1.057)

0.8496

Fetal hemoglobin (%)

0.929 (0.863,1.000)

0.0511

2407

0.916 (0.878,0.956)

0.0001

ACS rate (<0.2 yr-1 vs. ≥0.2 yr-1)

2.325 (1.267,4.265)

0.0064

2635

2.418 (1.799,3.249)

<0.0001

Renal insufficiency (Yes vs. No)

7.168 (3.687,13.936)

<0.0001

2635

3.922 (2.536,6.064)

<0.0001

Seizures (Yes vs. No)

1.275 (0.519,3.131)

0.5959

2635

2.405 (1.465,3.948)

0.0005

White-cell count (10 /L)

1.182 (1.085,1.287)

0.0001

2566

1.107 (1.057,1.160)

<0.0001

Asthma (Yes vs. No)

2.362 (1.208,4.621)

0.0120

1963

3.855 (2.081,7.140)

<0.0001

Age at study entry (yrs)

9

nificant risk factor for premature death among individuals
with SCA. Prior to the start of this study, we postulated
that asthma was a biologically plausible risk factor for premature death in individuals with SCA primarily because
asthma increases the prevalence of ACS episodes, a
known risk factor for death in this population.7 The mechanism of an association between asthma and death has not
been clarified by this study, but several observations about
asthma and SCA support such an association. Firstly, in
asthma, lung segments are obstructed by mucus and
edema before pulmonary blood flow can adjust.14 The
hypoxemia that results from ventilation-perfusion mismatch promotes local tissue hypoxia and sickling of red
blood cells15 possibly producing disease not only in the
lung (ACS episodes), but more distally in other organs
affected by SCA. Secondly, asthma is known to be associated with an increased incidence of ACS episodes which
in turn may increase the risk of chronic lung disease.16
Klings et al. recently described that pulmonary function
abnormalities are common in this cohort affecting up to
90% of individuals;17 however, no assessment of a physician’s diagnosis of asthma was included. Thirdly, asthma18
and SCA19-22 are both associated with a pro-inflammatory
state. Therefore, individuals with SCA and asthma would
also be expected to have additional complications related
to asthma and/or SCA. This is supported by evidence from
this cohort that suggests individuals with SCA and asthma
also have higher rates of pain and ACS.7 This study does
have limitations. The cohort for this analysis did not
include children under the age of 5. The diagnosis of asthma is more difficult in young children, and the impact of
transient wheezing and remitted asthma on lung function
and future SCA-morbidity has not been established.23,24
This analysis also has only limited ability to check for all
factors relating to death in individuals with SCA, such as
pulmonary hypertension, a more recently identified risk
factor which was not consistently reported in this cohort.25
In this analysis, we did check for known risk factors for
death in this cohort as previously reported. We are unable

to identify a direct cause and effect mechanism for the
association between asthma and premature death.
However, recognition of the association between SCA and
asthma is significant since established, evidence-based
acute and chronic treatment for asthma is available.
To summarize, based on the analysis of a large, well
characterized cohort of individuals with SCA, we have
demonstrated that asthma was associated with a significant increase in the risk of mortality. We provide evidence
that even after adjustment for the presence of ACS and
other known risk factors, asthma is an independent predictor of mortality in patients with SCA. Future prospective
studies to classify lung disease associated with SCA and
determine the effectiveness of asthma management in preventing SCA-related morbidity and mortality are warranted.

Appendix
The following investigators participated in the Co-operative
Study of Sickle Cell Disease: R. Johnson, Alta Bates Hospital,
Oakland, CA, USA.; L. McMahon, Boston City Hospital,
Boston, USA; O. Platt, Children's Hospital, Boston; F. Gill and
K. Ohene Frempong, Children's Hospital, Philadelphia; G.
Bray, J.F. Kelleher, and S. Leikin, Children's Hospital National
Medical Center, Washington, D.C.; E. Vichinsky and B. Lubin,
Children's Hospital, Oakland, Calif.; A. Bank and S. Piomelli,
Columbia Presbyterian Hospital, New York; W. Rosse, J.
Falletta, and T.R. Kinney, Duke University, Durham, N.C.; L.
Lessin, George Washington University, Washington, D.C.; J.
Smith and Y. Khakoo, Harlem Hospital, New York; R.B. Scott,
O. Castro, and C. Reindorf, Howard University, Washington,
D.C.; H. Dosik, S. Diamond, and R. Bellevue, Interfaith
Medical Center, Brooklyn, N.Y.; W. Wang and J. Wilimas,
LeBonheur Children's Hospital, Memphis, Tenn.; P. Milner,
Medical College of Georgia, Augusta; A. Brown, S. Miller, R.
Rieder, and P. Gillette, State University of New York Downstate
Medical Center, Brooklyn; W. Lande, S. Embury, and W.
Mentzer, San Francisco General Hospital, San Francisco; D.
Wethers and R. Grover, St. Luke's-Roosevelt Medical Center,
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New York; M. Koshy and N. Talishy, University of Illinois,
Chicago; C. Pegelow and P. Klug, University of Miami, Miami;
M. Steinberg, University of Mississippi, Jackson; A. Kraus,
University of Tennessee, Memphis; C. Dampier, Wyler
Children's Hospital, Chicago; H. Pearson and A.K. Ritchey, Yale
University, New Haven, Conn.; S. McKinlay, D. Gallagher, and
D. Brambilla, New England Research Institute, Watertown,
Mass, USA; and M. Gaston and C. Reid, National Heart,
Lung, and Blood Institute, Bethesda, Md.
The Co-operative Study of Sickle Cell Disease was conducted and supported by the National Heart, Lung and Blood
Institute in collaboration with site investigators. This manuscript
was not prepared in collaboration with investigators of the Cooperative Study of Sickle Cell Disease and does not necessarily
reflect the opinions or views of the Co-operative Study of Sickle
Cell Disease or National Heart, Lung and Blood Institute. The
principal investigator for this study had full access to all of the
data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
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